What Happened?
Beverly Hills, CA-based GT-Biopharma Appointed Anthony Cataldo as Chairman, Chief Executive Officer and President
About the Company
Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin`s lymphoma, acute myeloid leukemia and multiple solid tumors by leveraging our proprietary NK cell engager (TriKE™) platform technology.
About the Person
Anthony Cataldo is Chairman, Chief Executive Officer and President at GT Biopharma. Previously, Anthony held various senior HR leadership roles in the industry.
Info Source
News
Short Profile